Drug class
Rho(D) Immune Globulins
Rho(D) immune globulins are a specialized class of plasma-derived hyperimmune globulins containing high titers of antibodies directed against the Rh(D) antigen on red blood cells. Read more about Rho(D) Immune Globulins
6 drugs in this class 4 manufacturers
Drugs in Rho(D) Immune Globulins
MICRHOGAM ULTRA-FILTERED PLUS (Rho(D) immune globulin)
RHOGAM ULTRA-FILTERED PLUS (Rho(D) immune globulin)
RHOPHYLAC (Rho(D) immune globulin)
HYPERRHO S/D (Rho(D) immune globulin)
WINRHO SDF (Rho(D) immune globulin/maltose)
Rho(D) immune globulins are a specialized class of plasma-derived hyperimmune globulins containing high titers of antibodies directed against the Rh(D) antigen on red blood cells.
They function primarily through antibody-mediated immune suppression by binding to circulating Rh(D)-positive red blood cells and clearing them from maternal circulation before maternal active immunization can occur.
Clinically, these agents are primarily indicated in Rh-negative individuals to prevent Rh isoimmunization and hemolytic disease of the fetus and newborn following obstetric delivery, complications, procedures, or incompatible transfusions.
In addition, specific intravenous formulations are utilized in Rh-positive individuals to elevate platelet counts in immune thrombocytopenia by competitively saturating splenic Fc receptors and reducing platelet clearance.
-
fda.gov
Rho(D) immune globulins are a specialized class of plasma-derived hyperimmune globulins containing high titers of antibodies directed against the Rh(D) antigen on red blood cells They function primarily through antibody-mediated immune suppression by binding to circulating Rh(D)-positive red blood cells and clearing them from maternal circulation before maternal active immunization can occur
-
fda.gov
Rho(D) immune globulins are a specialized class of plasma-derived hyperimmune globulins containing high titers of antibodies directed against the Rh(D) antigen on red blood cells
-
fda.gov
They function primarily through antibody-mediated immune suppression by binding to circulating Rh(D)-positive red blood cells and clearing them from maternal circulation before maternal active immunization can occur In addition, specific intravenous formulations are utilized in Rh-positive individuals to elevate platelet counts in immune thrombocytopenia by competitively saturating splenic Fc receptors and reducing platelet clearance
-
fda.gov
Clinically, these agents are primarily indicated in Rh-negative individuals to prevent Rh isoimmunization and hemolytic disease of the fetus and newborn following obstetric delivery, complications, procedures, or incompatible transfusions
-
fda.gov
Clinically, these agents are primarily indicated in Rh-negative individuals to prevent Rh isoimmunization and hemolytic disease of the fetus and newborn following obstetric delivery, complications, procedures, or incompatible transfusions In addition, specific intravenous formulations are utilized in Rh-positive individuals to elevate platelet counts in immune thrombocytopenia by competitively saturating splenic Fc receptors and reducing platelet clearance
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.